Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

Salamanders are more sensitive to a skin-eating fungus at colder temperatures, pointing to locations of North America where pathogen invasion is most likely.

Vanderbilt researchers have linked bone-related complications of severely injured patients — findings that could help minimize these complications.

Adam Seegmiller, MD, PhD, has been named the inaugural vice chair for Clinical Affairs in the Department of Pathology, Microbiology and Immunology as well as executive medical director of the newly formed Pathology and Laboratory Medicine — Clinical Service Center.